2022-04-14 | NYSE:BHVN | Press release

  • More than 25% of patients report being severely or very severely affected by their migraine attacks
  • A study showed that higher levels of migraine-related disability were associated with increased UNHCR costs in primary and specialty care settings in adults with episodic migraine
  • Data suggest that assessing disability in people with migraine can support the prescription of cost-effective interventions, especially in people with severe disability

NEW HAVEN, Conn., April 14, 2022 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the release of a new real-world study showing that as migraine-related disability increases, so does healthcare utilization among Americans with episodic migraine. Targeting high-disability patients with effective treatments can reduce disability and improve the cost-effectiveness of medical care among primary and specialty care providers. These results were published in the March issue of Headaches: The Headache and Face Diarythe official journal of the American Headache Society.

Participants in this retrospective cohort study were identified using claims data and electronic health records from the Decision Resources Group database. Adults (aged ≥ 18 years) were eligible if they had been diagnosed with migraine with or without aura as defined by International Classification of Diseases codes (ICD-9 or ICD-10) and completed a questionnaire MIDAS (Migraine Disability Assessment Scale) between January 2016 and December 2018. Researchers explored the associations between migraine-related disability, as measured by the MIDAS score, and the cost of HCRU during the 6 months following the MIDAS assessment in primary and specialty care settings.

One of the study’s important findings is that of the 7,662 adults analyzed, 26% (1,982) reported severe or very severe disability. This translates to a median of approximately 33 days per quarter (based on source data) during which migraine patients were either unable to continue activities of daily living (absenteeism) or were severely impaired in these activities (presenteeism). Six-month adjusted cost estimates, summarized in Figures 1 and 2, showed that higher levels of migraine-related disability were associated with increased medical and pharmaceutical costs.

“This study describes the relationships between MIDAS scores, healthcare resource utilization, and direct medical costs,” said Richard Lipton, MD, professor and vice president of neurology at the Albert Einstein College of Medicine, who developed the MIDAS instrument and is the study’s senior author. “Our results suggest that disability ratings in people with migraine can be used to target those who have the most to gain from effective treatment. The cost offsets of effective treatment should be assessed in these most disabled and expensive patient groups.”

Gil L’Italien Ph.D., Senior Vice President, GHEOR & Epidemiology, Biohaven, and co-author of the study, observed, “This analysis, derived from claims and health records data representing 90% health plans in United States further highlights the association between migraine-related disability and health care resource utilization, and establishes the MIDAS questionnaire as a useful tool for predicting and potentially controlling the costs associated with migraine management.

About Migraines

Nearly 40 million people in the United States suffer from migraine, and the World Health Organization ranks migraine among the 10 most debilitating medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that may be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia). There is a significant unmet need for new treatments, as more than 90% of migraine sufferers are unable to work or function normally during an attack.

About Biohaven

Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven’s Neuroinnovation™ portfolio includes FDA-approved NURTEC® ODT (rimegepant) for the acute and preventive treatment of migraine and a broad portfolio of late-stage product candidates on three distinct mechanistic platforms: antagonism of CGRP receptors for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia; MPO inhibition for amyotrophic lateral sclerosis; Ion channel activators Kv7 (Kv7) and myostatin. More information about Biohaven is available at www.biohavenpharma.com and Nurtec ODT at www.nurtec.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties, including statements regarding the ability to market NURTEC®️ ODT (rimegepant), delays or problems in sourcing or manufacturing a commercial product, compliance with applicable U.S. regulatory requirements, timing, commencement and anticipated results of planned and ongoing clinical trials of Biohaven, timing of anticipated interactions with the FDA, timing and outcome of regulatory filings, potential commercialization of Biohaven’s product candidates, potential for Biohaven’s product candidates to be first-in-class or best-in-class treatments, and the efficacy and safety of the product candidates from Biohaven. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Other important factors to consider in making forward-looking statements are described in the “Risk Factors” section of Biohaven’s Annual Report on Form 10-K for the fiscal year ended. December 31, 2021filed with the Securities and Exchange Commission on February 25, 2022, and Biohaven’s subsequent filings with the Securities and Exchange Commission. Forward-looking statements are made as of this date, and Biohaven undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Neuroinnovation is a registered trademark of Biohaven Pharmaceutical Holding Company Ltd.

Contact

Jennifer Porcelli

Vice President, Investor Relations

[email protected]

201-248-0741

Media Contact

Mike Beyer

Sam Brown Inc.

[email protected]

312-961-2502

FIGURE 2 Average pharmaceutical costs (95% CI) 6 months after index by MIDAS grade (expected costs derived from multivariate GLM).  Control variables that were mostly common across all GLMs included gender, Charlson score, migraine flag, MIDAS grade, preventative medications, and rescue medications.  CI, confidence interval;  GLM, generalized linear model;  MIDAS, assessment of migraine disability

(PRNewsfoto/Biohaven Pharmaceutical Holding)

Quote Show original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-real-world-study-highlights-increased-healthcare-utilization-among-americans-with-episodic-migraine-having-higher-levels-of-migraine- disability-related-301525370.html

SOURCE Biohaven Pharmaceutical Holding Company Ltd.